BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 38345092)

  • 1. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
    Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
    Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
    Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
    Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
    Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
    Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
    Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
    Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
    Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
    Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
    Giménez E; Guerreiro M; Torres I; Aguilar C; Albert E; Hernández-Boluda JC; Hernani R; Pérez A; Amat P; Piñana JL; Montoro J; Solano C; Navarro D
    Transpl Infect Dis; 2023 Apr; 25(2):e14021. PubMed ID: 36748748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
    Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
    Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data.
    Mori Y; Jinnouchi F; Takenaka K; Aoki T; Kuriyama T; Kadowaki M; Odawara J; Ueno T; Kohno K; Harada T; Yoshimoto G; Takase K; Henzan H; Kato K; Ito Y; Kamimura T; Ohno Y; Ogawa R; Eto T; Nagafuji K; Akashi K; Miyamoto T
    Bone Marrow Transplant; 2021 Apr; 56(4):853-862. PubMed ID: 33139867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.
    Koch K; Osswald L; Miller I; Braitsch K; Götze K; Bassermann F; Herhaus P; Verbeek M
    Anticancer Res; 2022 Nov; 42(11):5431-5441. PubMed ID: 36288861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis.
    Mori Y; Harada T; Yoshimoto G; Shima T; Numata A; Jinnouchi F; Yamauchi T; Kikushige Y; Kunisaki Y; Kato K; Takenaka K; Akashi K; Miyamoto T
    Int J Hematol; 2022 Aug; 116(2):258-265. PubMed ID: 35524024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
    Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
    Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
    Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM
    Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
    Galaverna F; Baccelli F; Zama D; Tridello G; Masetti R; Soncini E; Mura R; Barzaghi F; Colombini A; Prunotto G; D'Amico MR; Calore E; Biffi A; Perruccio K; Gasperini P; Oltolini C; Quagliarella F; Giacomazzi A; Pagliara D; Locatelli F; Cesaro S
    Bone Marrow Transplant; 2024 Apr; 59(4):505-512. PubMed ID: 38272999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: A narrative review.
    Solano C; Giménez E; Albert E; Piñana JL; Navarro D
    J Med Virol; 2023 Aug; 95(8):e29005. PubMed ID: 37526411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
    Hinman B; Cox J; Umoru G; Kamble R; Musick W
    Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
    Kampouri E; Zamora D; Kiem ES; Liu W; Ibrahimi S; Blazevic RL; Lovas EA; Kimball LE; Huang ML; Jerome KR; Ueda Oshima M; Mielcarek M; Zerr DM; Boeckh MJ; Krantz EM; Hill JA
    Clin Microbiol Infect; 2023 Nov; 29(11):1450.e1-1450.e7. PubMed ID: 37532126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study.
    Studer U; Khanna N; Leuzinger K; Hirsch HH; Heim D; Lengerke C; Tsakiris DA; Halter J; Gerull S; Passweg J; Medinger M; Gwerder M
    Anticancer Res; 2020 Oct; 40(10):5909-5917. PubMed ID: 32988922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.